"Medicare's Potential Expansion of Weight-Loss Drug Coverage and Heart Disease Prevention"
TL;DR Summary
Novo Nordisk's obesity drug Wegovy, now approved for reducing the risk of major heart complications for overweight or obese individuals with existing heart disease, could potentially open up access to the drug for Medicare patients, despite Medicare's current prohibition on covering medications for obesity treatment alone. This FDA approval may provide a pathway for doctors to prescribe the drug to some Medicare patients, offering a potential workaround to the existing coverage restrictions.
- Medicare coverage of Wegovy, once blocked, now looks possible - STAT STAT
- How Medicare could increase access to weight-loss drugs Axios
- The Ozempic Revolution Is Stuck The Atlantic
- Wegovy Approved By FDA to Reduce Heart Attack Risk The New York Times
- Wegovy Approved for Major Heart Disease Prevention Medpage Today
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
1 min
vs 1 min read
Condensed
63%
196 → 72 words
Want the full story? Read the original article
Read on STAT